.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
QuintilesIMS
Boehringer Ingelheim
McKesson
Federal Trade Commission
Novartis
Chubb
Harvard Business School
US Department of Justice
Teva

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018655

« Back to Dashboard

NDA 018655 describes NORPACE CR, which is a drug marketed by Gd Searle Llc and is included in one NDA. It is available from two suppliers. Additional details are available on the NORPACE CR profile page.

The generic ingredient in NORPACE CR is disopyramide phosphate. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.

Summary for 018655

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 018655

Medical Subject Heading (MeSH) Categories for 018655

Suppliers and Packaging for NDA: 018655

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NORPACE CR disopyramide phosphate CAPSULE, EXTENDED RELEASE;ORAL 018655 NDA G.D. Searle LLC Division of Pfizer Inc 0025-2732 0025-2732-31 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2732-31)
NORPACE CR disopyramide phosphate CAPSULE, EXTENDED RELEASE;ORAL 018655 NDA G.D. Searle LLC Division of Pfizer Inc 0025-2732 0025-2732-34 100 CAPSULE, EXTENDED RELEASE in 1 BOX, UNIT-DOSE (0025-2732-34)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 100MG BASE
Approval Date:Jul 20, 1982TE:RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 150MG BASE
Approval Date:Jul 20, 1982TE:ABRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Fuji
Novartis
Mallinckrodt
Julphar
US Department of Justice
Accenture
Federal Trade Commission
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot